Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
特瑞普利单抗联合仑伐替尼对比安慰剂联合仑伐替尼一线治疗晚期肝细胞癌
CTR20201226Phase 3Active
- Sponsor
- Junshi Biosciences
- Start
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in hepatocellular carcinoma (HCC), sponsored by Junshi Biosciences. Started Jul 2020; status: active.
02
Drugs
toripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20201226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201226.